PMID: 7027623Jan 1, 1981Paper

Limited value of in vitro techniques for the detection of leukocyte alloantibodies during granulocyte transfusion therapy

Vox Sanguinis
M WiesnethR Arnold

Abstract

A 23-year-old male patient undergoing first induction chemotherapy for acute myeloid leukaemia received granulocyte transfusions on 10 consecutive days. An average of 2.1 X 10(10) granulocytes was given per square metre body surface area per day. Transfusion reactions and absence of post-transfusion granulocyte increment after the fifth granulocyte transfusion suggested the presence of leukocyte antibodies. However, no antibodies were detectable at this time by the lymphocytotoxicity test, the indirect granulocyte immunofluorescence test, or the platelet suspension immunofluorescence test. In contrast to the clinical observation, the serological detection of leukocyte antibodies was only possible 1 day after the last granulocyte transfusion.

References

Jan 1, 1979·CRC Critical Reviews in Clinical Laboratory Sciences·J McCullough
Aug 1, 1977·British Journal of Haematology·F W VerheugtC P Engelfriet
Jun 1, 1978·British Journal of Haematology·A E von dem BorneC P Engelfriet
Apr 10, 1975·The New England Journal of Medicine·D J HigbyJ F Holland
Aug 24, 1972·The New England Journal of Medicine·R G GrawE S Henderson
Aug 24, 1968·Nature·A Svejgaard, F Kissmeyer-Nielsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.